Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
QHC / Quorum Health Corporation / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us74909e1064_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) QUORUM HEALTH CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 74909E106 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this co
QHC

1
QHC / Quorum Health Corporation / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us74909e1064_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) QUORUM HEALTH CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 74909E106 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this co
QHC

6
QHC / Quorum Health Corporation FORM 8-K (Current Report)

2018-06-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
QHC

8
What Falling Estimates & Price Mean for Quorum Health (QHC)

2018-06-04 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Quorum Health Corporation (QHC - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
ADUS QHC MTEM

4
QHC / Quorum Health Corporation / MORGAN STANLEY - MS INITIAL (Passive Investment)

2018-05-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Quorum Health Corp ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 74909E106 ---------------------------------
QHC

5
QHC / Quorum Health Corporation / MORGAN STANLEY - MS INITIAL (Passive Investment)

2018-05-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Quorum Health Corp ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 74909E106 ---------------------------------
QHC

5
QHC / Quorum Health Corporation FORM 8-K (Current Report)

2018-05-28 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
QHC

7
QHC / Quorum Health Corporation FORM 8-K (Current Report)

2018-05-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
QHC

5
Quorum Health Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Quorum Health Corporation in conjunction with their 2018 Q1 earnings call.
QHC

16
Quorum Health's (QHC) CEO Tom Miller on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good morning. My name is Heidi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Quorum Health Corporation First Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
MS.PRI MS.PRK QHC MS.PRE MS.PRF MS.PRG MS MS.PRA

4
BRIEF-Quorum Health Says As Of March 31, Co Incurred About $13.7 Mln Of Costs Related To Closure Of Affinity

2018-05-10 reuters
* QUORUM HEALTH SAYS AS OF MARCH 31, CO INCURRED ABOUT $13.7 MILLION OF COSTS RELATED TO CLOSURE OF AFFINITY - SEC FILING
QHC

6
QHC / Quorum Health Corporation 8-K (Current Report)

2018-05-10 sec.gov
qhc-8k_20180509.htm UNITED STATES
QHC

6
QHC / Quorum Health Corporation 10-Q (Quarterly Report)

2018-05-10 sec.gov
qhc-10q_20180331.htm fSep2
QHC

4
QHC / Quorum Health Corporation 8-K/A (Current Report)

2018-05-10 sec.gov
qhc-8ka_20180105.htm UNITED STATES
QHC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 74909E106